Skip to main content
. 2022 Jul 6;10(7):e004487. doi: 10.1136/jitc-2022-004487

Figure 2.

Figure 2

Dynamic changes in serum CEA and circulating NPY/SEPT9/WIF1 DNA methylation of 4 CRLM patients. Bev, bevacizumab; CEA, carcinoembryonic antigen; chemo, chemotherapy; CRLM, colorectal cancer liver metastases; ICI, immune checkpoint inhibitor; meth-cfDNA, circulating cell-free DNA methylation; pCR, pathological complete response.